Increlex (mecasermin)
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 64 (Table of Contents)
Published: 5 Oct-2005
DOI: 10.3833/pdr.v2005.i64.610 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
The use of insulin-like growth factor-1 (IGF-1, mecasermin) for treating growth hormone insensitivity syndrome (GHIS) originated with Fujisawa Pharmaceutical (now Astellas Pharma) in Japan, where it was granted Orphan Drug Status for both GHIS and for severe insulin-resistant diabetes in November 1993...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS